Spine Biopharma
- | Biotech or pharma, therapeutic R&D
SB-01 is a 1st-in-class, therapeutic for the treatment of degenerative disc disease, offering potential clinical benefits of pain relief, restoration of function and potential prevention of disease progression. Phase 3 study dosed 1st patient Sept 2022. Expected Phase 3 data readout, Q2' 2025.
Address
New YorkNew York
United States
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}